Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Biodesix (BDSX) EBT Margin (2019 - 2025)

Historic EBT Margin for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to 41.92%.

  • Biodesix's EBT Margin rose 166600.0% to 41.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 49.85%, marking a year-over-year increase of 165800.0%. This contributed to the annual value of 59.95% for FY2024, which is 437000.0% up from last year.
  • Biodesix's EBT Margin amounted to 41.92% in Q3 2025, which was up 166600.0% from 58.03% recorded in Q2 2025.
  • Over the past 5 years, Biodesix's EBT Margin peaked at 21.6% during Q1 2021, and registered a low of 238.21% during Q1 2022.
  • In the last 5 years, Biodesix's EBT Margin had a median value of 91.44% in 2024 and averaged 107.16%.
  • As far as peak fluctuations go, Biodesix's EBT Margin surged by 1722600bps in 2021, and later plummeted by -2166100bps in 2022.
  • Over the past 5 years, Biodesix's EBT Margin (Quarter) stood at 182.38% in 2021, then increased by 6bps to 171.13% in 2022, then soared by 63bps to 62.71% in 2023, then soared by 34bps to 41.12% in 2024, then fell by -2bps to 41.92% in 2025.
  • Its last three reported values are 41.92% in Q3 2025, 58.03% for Q2 2025, and 60.26% during Q1 2025.